1 Report Business Overview
    1.1 Study Scope
    1.2 Market Analysis by Type
        1.2.1 Global Targeted Drugs for NSCLC Market Size Growth Rate by Type, 2017 VS 2021 VS 2028
        1.2.2 Target EGFR
        1.2.3 Target ALK
        1.2.4 Target HER2
        1.2.5 Target ROS1
        1.2.6 Target BRAF
        1.2.7 Target MEK
        1.2.8 Target VEGFR2
        1.2.9 Target VEGF
        1.2.10 Target MET
    1.3 Market by Application
        1.3.1 Global Targeted Drugs for NSCLC Market Size Growth Rate by Application, 2017 VS 2021 VS 2028
        1.3.2 Squamous Cell Carcinoma of NSCLC
        1.3.3 Adenocarcinoma of NSCLC
        1.3.4 Large Cell Carcinoma of NSCLC
    1.4 Study Objectives
    1.5 Years Considered
2 Global Growth Trends
    2.1 Global Targeted Drugs for NSCLC Market Perspective (2017-2028)
    2.2 Targeted Drugs for NSCLC Growth Trends by Region
        2.2.1 Targeted Drugs for NSCLC Market Size by Region: 2017 VS 2021 VS 2028
        2.2.2 Targeted Drugs for NSCLC Historic Market Size by Region (2017-2022)
        2.2.3 Targeted Drugs for NSCLC Forecasted Market Size by Region (2023-2028)
    2.3 Targeted Drugs for NSCLC Market Dynamics
        2.3.1 Targeted Drugs for NSCLC Industry Trends
        2.3.2 Targeted Drugs for NSCLC Market Drivers
        2.3.3 Targeted Drugs for NSCLC Market Challenges
        2.3.4 Targeted Drugs for NSCLC Market Restraints
3 Competition Landscape by Key Players
    3.1 Global Top Targeted Drugs for NSCLC Players by Revenue
        3.1.1 Global Top Targeted Drugs for NSCLC Players by Revenue (2017-2022)
        3.1.2 Global Targeted Drugs for NSCLC Revenue Market Share by Players (2017-2022)
    3.2 Global Targeted Drugs for NSCLC Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
    3.3 Players Covered: Ranking by Targeted Drugs for NSCLC Revenue
    3.4 Global Targeted Drugs for NSCLC Market Concentration Ratio
        3.4.1 Global Targeted Drugs for NSCLC Market Concentration Ratio (CR5 and HHI)
        3.4.2 Global Top 10 and Top 5 Companies by Targeted Drugs for NSCLC Revenue in 2021
    3.5 Targeted Drugs for NSCLC Key Players Head office and Area Served
    3.6 Key Players Targeted Drugs for NSCLC Product Solution and Service
    3.7 Date of Enter into Targeted Drugs for NSCLC Market
    3.8 Mergers & Acquisitions, Expansion Plans
4 Targeted Drugs for NSCLC Breakdown Data by Type
    4.1 Global Targeted Drugs for NSCLC Historic Market Size by Type (2017-2022)
    4.2 Global Targeted Drugs for NSCLC Forecasted Market Size by Type (2023-2028)
5 Targeted Drugs for NSCLC Breakdown Data by Application
    5.1 Global Targeted Drugs for NSCLC Historic Market Size by Application (2017-2022)
    5.2 Global Targeted Drugs for NSCLC Forecasted Market Size by Application (2023-2028)
6 North America
    6.1 North America Targeted Drugs for NSCLC Market Size (2017-2028)
    6.2 North America Targeted Drugs for NSCLC Market Size by Type
        6.2.1 North America Targeted Drugs for NSCLC Market Size by Type (2017-2022)
        6.2.2 North America Targeted Drugs for NSCLC Market Size by Type (2023-2028)
        6.2.3 North America Targeted Drugs for NSCLC Market Share by Type (2017-2028)
    6.3 North America Targeted Drugs for NSCLC Market Size by Application
        6.3.1 North America Targeted Drugs for NSCLC Market Size by Application (2017-2022)
        6.3.2 North America Targeted Drugs for NSCLC Market Size by Application (2023-2028)
        6.3.3 North America Targeted Drugs for NSCLC Market Share by Application (2017-2028)
    6.4 North America Targeted Drugs for NSCLC Market Size by Country
        6.4.1 North America Targeted Drugs for NSCLC Market Size by Country (2017-2022)
        6.4.2 North America Targeted Drugs for NSCLC Market Size by Country (2023-2028)
        6.4.3 U.S.
        6.4.4 Canada
7 Europe
    7.1 Europe Targeted Drugs for NSCLC Market Size (2017-2028)
    7.2 Europe Targeted Drugs for NSCLC Market Size by Type
        7.2.1 Europe Targeted Drugs for NSCLC Market Size by Type (2017-2022)
        7.2.2 Europe Targeted Drugs for NSCLC Market Size by Type (2023-2028)
        7.2.3 Europe Targeted Drugs for NSCLC Market Share by Type (2017-2028)
    7.3 Europe Targeted Drugs for NSCLC Market Size by Application
        7.3.1 Europe Targeted Drugs for NSCLC Market Size by Application (2017-2022)
        7.3.2 Europe Targeted Drugs for NSCLC Market Size by Application (2023-2028)
        7.3.3 Europe Targeted Drugs for NSCLC Market Share by Application (2017-2028)
    7.4 Europe Targeted Drugs for NSCLC Market Size by Country
        7.4.1 Europe Targeted Drugs for NSCLC Market Size by Country (2017-2022)
        7.4.2 Europe Targeted Drugs for NSCLC Market Size by Country (2023-2028)
        7.4.3 Germany
        7.4.4 France
        7.4.5 U.K.
        7.4.6 Italy
        7.4.7 Russia
        7.4.8 Nordic Countries
8 Asia-Pacific
    8.1 Asia-Pacific Targeted Drugs for NSCLC Market Size (2017-2028)
    8.2 Asia-Pacific Targeted Drugs for NSCLC Market Size by Type
        8.2.1 Asia-Pacific Targeted Drugs for NSCLC Market Size by Type (2017-2022)
        8.2.2 Asia-Pacific Targeted Drugs for NSCLC Market Size by Type (2023-2028)
        8.2.3 Asia-Pacific Targeted Drugs for NSCLC Market Share by Type (2017-2028)
    8.3 Asia-Pacific Targeted Drugs for NSCLC Market Size by Application
        8.3.1 Asia-Pacific Targeted Drugs for NSCLC Market Size by Application (2017-2022)
        8.3.2 Asia-Pacific Targeted Drugs for NSCLC Market Size by Application (2023-2028)
        8.3.3 Asia-Pacific Targeted Drugs for NSCLC Market Share by Application (2017-2028)
    8.4 Asia-Pacific Targeted Drugs for NSCLC Market Size by Region
        8.4.1 Asia-Pacific Targeted Drugs for NSCLC Market Size by Region (2017-2022)
        8.4.2 Asia-Pacific Targeted Drugs for NSCLC Market Size by Region (2023-2028)
        8.4.3 China
        8.4.4 Japan
        8.4.5 South Korea
        8.4.6 Southeast Asia
        8.4.7 India
        8.4.8 Australia 
9 Latin America
    9.1 Latin America Targeted Drugs for NSCLC Market Size (2017-2028)
    9.2 Latin America Targeted Drugs for NSCLC Market Size by Type
        9.2.1 Latin America Targeted Drugs for NSCLC Market Size by Type (2017-2022)
        9.2.2 Latin America Targeted Drugs for NSCLC Market Size by Type (2023-2028)
        9.2.3 Latin America Targeted Drugs for NSCLC Market Share by Type (2017-2028)
    9.3 Latin America Targeted Drugs for NSCLC Market Size by Application
        9.3.1 Latin America Targeted Drugs for NSCLC Market Size by Application (2017-2022)
        9.3.2 Latin America Targeted Drugs for NSCLC Market Size by Application (2023-2028)
        9.3.3 Latin America Targeted Drugs for NSCLC Market Share by Application (2017-2028)
    9.4 Latin America Targeted Drugs for NSCLC Market Size by Country
        9.4.1 Latin America Targeted Drugs for NSCLC Market Size by Country (2017-2022)
        9.4.2 Latin America Targeted Drugs for NSCLC Market Size by Country (2023-2028)
        9.4.3 Mexico
        9.4.4 Brazil
10 Middle East & Africa
    10.1 Middle East & Africa Targeted Drugs for NSCLC Market Size (2017-2028)
    10.2 Middle East & Africa Targeted Drugs for NSCLC Market Size by Type
        10.2.1 Middle East & Africa Targeted Drugs for NSCLC Market Size by Type (2017-2022)
        10.2.2 Middle East & Africa Targeted Drugs for NSCLC Market Size by Type (2023-2028)
        10.2.3 Middle East & Africa Targeted Drugs for NSCLC Market Share by Type (2017-2028)
    10.3 Middle East & Africa Targeted Drugs for NSCLC Market Size by Application
        10.3.1 Middle East & Africa Targeted Drugs for NSCLC Market Size by Application (2017-2022)
        10.3.2 Middle East & Africa Targeted Drugs for NSCLC Market Size by Application (2023-2028)
        10.3.3 Middle East & Africa Targeted Drugs for NSCLC Market Share by Application (2017-2028)
    10.4 Middle East & Africa Targeted Drugs for NSCLC Market Size by Country
        10.4.1 Middle East & Africa Targeted Drugs for NSCLC Market Size by Country (2017-2022)
        10.4.2 Middle East & Africa Targeted Drugs for NSCLC Market Size by Country (2023-2028)
        10.4.3 Turkey
        10.4.4 Saudi Arabia
        10.4.5 UAE
11 Key Players Profiles
    11.1 Allergan
        11.1.1 Allergan Company Details
        11.1.2 Allergan Business Overview
        11.1.3 Allergan Targeted Drugs for NSCLC Introduction
        11.1.4 Allergan Revenue in Targeted Drugs for NSCLC Business (2017-2022)
        11.1.5 Allergan Recent Developments
    11.2 Amgen
        11.2.1 Amgen Company Details
        11.2.2 Amgen Business Overview
        11.2.3 Amgen Targeted Drugs for NSCLC Introduction
        11.2.4 Amgen Revenue in Targeted Drugs for NSCLC Business (2017-2022)
        11.2.5 Amgen Recent Developments
    11.3 ARIAD Pharmaceuticals (Takeda)
        11.3.1 ARIAD Pharmaceuticals (Takeda) Company Details
        11.3.2 ARIAD Pharmaceuticals (Takeda) Business Overview
        11.3.3 ARIAD Pharmaceuticals (Takeda) Targeted Drugs for NSCLC Introduction
        11.3.4 ARIAD Pharmaceuticals (Takeda) Revenue in Targeted Drugs for NSCLC Business (2017-2022)
        11.3.5 ARIAD Pharmaceuticals (Takeda) Recent Developments
    11.4 Beacon Pharma Limited
        11.4.1 Beacon Pharma Limited Company Details
        11.4.2 Beacon Pharma Limited Business Overview
        11.4.3 Beacon Pharma Limited Targeted Drugs for NSCLC Introduction
        11.4.4 Beacon Pharma Limited Revenue in Targeted Drugs for NSCLC Business (2017-2022)
        11.4.5 Beacon Pharma Limited Recent Developments
    11.5 BeiGene
        11.5.1 BeiGene Company Details
        11.5.2 BeiGene Business Overview
        11.5.3 BeiGene Targeted Drugs for NSCLC Introduction
        11.5.4 BeiGene Revenue in Targeted Drugs for NSCLC Business (2017-2022)
        11.5.5 BeiGene Recent Developments
    11.6 Biocon
        11.6.1 Biocon Company Details
        11.6.2 Biocon Business Overview
        11.6.3 Biocon Targeted Drugs for NSCLC Introduction
        11.6.4 Biocon Revenue in Targeted Drugs for NSCLC Business (2017-2022)
        11.6.5 Biocon Recent Developments
    11.7 Boehringer-Ingelheim
        11.7.1 Boehringer-Ingelheim Company Details
        11.7.2 Boehringer-Ingelheim Business Overview
        11.7.3 Boehringer-Ingelheim Targeted Drugs for NSCLC Introduction
        11.7.4 Boehringer-Ingelheim Revenue in Targeted Drugs for NSCLC Business (2017-2022)
        11.7.5 Boehringer-Ingelheim Recent Developments
    11.8 Celgene Corporation
        11.8.1 Celgene Corporation Company Details
        11.8.2 Celgene Corporation Business Overview
        11.8.3 Celgene Corporation Targeted Drugs for NSCLC Introduction
        11.8.4 Celgene Corporation Revenue in Targeted Drugs for NSCLC Business (2017-2022)
        11.8.5 Celgene Corporation Recent Developments
    11.9 Drug International Limted
        11.9.1 Drug International Limted Company Details
        11.9.2 Drug International Limted Business Overview
        11.9.3 Drug International Limted Targeted Drugs for NSCLC Introduction
        11.9.4 Drug International Limted Revenue in Targeted Drugs for NSCLC Business (2017-2022)
        11.9.5 Drug International Limted Recent Developments
    11.10 Fujifilm Kyowa Kirin Biologics
        11.10.1 Fujifilm Kyowa Kirin Biologics Company Details
        11.10.2 Fujifilm Kyowa Kirin Biologics Business Overview
        11.10.3 Fujifilm Kyowa Kirin Biologics Targeted Drugs for NSCLC Introduction
        11.10.4 Fujifilm Kyowa Kirin Biologics Revenue in Targeted Drugs for NSCLC Business (2017-2022)
        11.10.5 Fujifilm Kyowa Kirin Biologics Recent Developments
    11.11 Genvio Pharma Limited
        11.11.1 Genvio Pharma Limited Company Details
        11.11.2 Genvio Pharma Limited Business Overview
        11.11.3 Genvio Pharma Limited Targeted Drugs for NSCLC Introduction
        11.11.4 Genvio Pharma Limited Revenue in Targeted Drugs for NSCLC Business (2017-2022)
        11.11.5 Genvio Pharma Limited Recent Developments
    11.12 Hetero Drugs
        11.12.1 Hetero Drugs Company Details
        11.12.2 Hetero Drugs Business Overview
        11.12.3 Hetero Drugs Targeted Drugs for NSCLC Introduction
        11.12.4 Hetero Drugs Revenue in Targeted Drugs for NSCLC Business (2017-2022)
        11.12.5 Hetero Drugs Recent Developments
    11.13 ImClone Systems ?(Eli Lilly)
        11.13.1 ImClone Systems ?(Eli Lilly) Company Details
        11.13.2 ImClone Systems ?(Eli Lilly) Business Overview
        11.13.3 ImClone Systems ?(Eli Lilly) Targeted Drugs for NSCLC Introduction
        11.13.4 ImClone Systems ?(Eli Lilly) Revenue in Targeted Drugs for NSCLC Business (2017-2022)
        11.13.5 ImClone Systems ?(Eli Lilly) Recent Developments
    11.14 Incepta Pharmaceuticals
        11.14.1 Incepta Pharmaceuticals Company Details
        11.14.2 Incepta Pharmaceuticals Business Overview
        11.14.3 Incepta Pharmaceuticals Targeted Drugs for NSCLC Introduction
        11.14.4 Incepta Pharmaceuticals Revenue in Targeted Drugs for NSCLC Business (2017-2022)
        11.14.5 Incepta Pharmaceuticals Recent Developments
    11.15 Mylan
        11.15.1 Mylan Company Details
        11.15.2 Mylan Business Overview
        11.15.3 Mylan Targeted Drugs for NSCLC Introduction
        11.15.4 Mylan Revenue in Targeted Drugs for NSCLC Business (2017-2022)
        11.15.5 Mylan Recent Developments
    11.16 Novartis
        11.16.1 Novartis Company Details
        11.16.2 Novartis Business Overview
        11.16.3 Novartis Targeted Drugs for NSCLC Introduction
        11.16.4 Novartis Revenue in Targeted Drugs for NSCLC Business (2017-2022)
        11.16.5 Novartis Recent Developments
    11.17 Pfizer
        11.17.1 Pfizer Company Details
        11.17.2 Pfizer Business Overview
        11.17.3 Pfizer Targeted Drugs for NSCLC Introduction
        11.17.4 Pfizer Revenue in Targeted Drugs for NSCLC Business (2017-2022)
        11.17.5 Pfizer Recent Developments
    11.18 Reliance Lifesciences
        11.18.1 Reliance Lifesciences Company Details
        11.18.2 Reliance Lifesciences Business Overview
        11.18.3 Reliance Lifesciences Targeted Drugs for NSCLC Introduction
        11.18.4 Reliance Lifesciences Revenue in Targeted Drugs for NSCLC Business (2017-2022)
        11.18.5 Reliance Lifesciences Recent Developments
    11.19 Roche
        11.19.1 Roche Company Details
        11.19.2 Roche Business Overview
        11.19.3 Roche Targeted Drugs for NSCLC Introduction
        11.19.4 Roche Revenue in Targeted Drugs for NSCLC Business (2017-2022)
        11.19.5 Roche Recent Developments
    11.20 AstraZeneca
        11.20.1 AstraZeneca Company Details
        11.20.2 AstraZeneca Business Overview
        11.20.3 AstraZeneca Targeted Drugs for NSCLC Introduction
        11.20.4 AstraZeneca Revenue in Targeted Drugs for NSCLC Business (2017-2022)
        11.20.5 AstraZeneca Recent Developments
    11.21 Cipla
        11.21.1 Cipla Company Details
        11.21.2 Cipla Business Overview
        11.21.3 Cipla Targeted Drugs for NSCLC Introduction
        11.21.4 Cipla Revenue in Targeted Drugs for NSCLC Business (2017-2022)
        11.21.5 Cipla Recent Developments
    11.22 Teva
        11.22.1 Teva Company Details
        11.22.2 Teva Business Overview
        11.22.3 Teva Targeted Drugs for NSCLC Introduction
        11.22.4 Teva Revenue in Targeted Drugs for NSCLC Business (2017-2022)
        11.22.5 Teva Recent Developments
    11.23 OSI Pharmaceuticals
        11.23.1 OSI Pharmaceuticals Company Details
        11.23.2 OSI Pharmaceuticals Business Overview
        11.23.3 OSI Pharmaceuticals Targeted Drugs for NSCLC Introduction
        11.23.4 OSI Pharmaceuticals Revenue in Targeted Drugs for NSCLC Business (2017-2022)
        11.23.5 OSI Pharmaceuticals Recent Developments
    11.24 Glenmark Pharmaceuticals
        11.24.1 Glenmark Pharmaceuticals Company Details
        11.24.2 Glenmark Pharmaceuticals Business Overview
        11.24.3 Glenmark Pharmaceuticals Targeted Drugs for NSCLC Introduction
        11.24.4 Glenmark Pharmaceuticals Revenue in Targeted Drugs for NSCLC Business (2017-2022)
        11.24.5 Glenmark Pharmaceuticals Recent Developments
    11.25 Natco Pharma
        11.25.1 Natco Pharma Company Details
        11.25.2 Natco Pharma Business Overview
        11.25.3 Natco Pharma Targeted Drugs for NSCLC Introduction
        11.25.4 Natco Pharma Revenue in Targeted Drugs for NSCLC Business (2017-2022)
        11.25.5 Natco Pharma Recent Developments
12 Analyst's Viewpoints/Conclusions
13 Appendix
    13.1 Research Methodology
        13.1.1 Methodology/Research Approach
        13.1.2 Data Source
    13.2 Author Details
    13.3 Disclaimer
                  
              

                

                 
List of Tables
    Table 1. Global Targeted Drugs for NSCLC Market Size Growth Rate by Type (US$ Million), 2017 VS 2021 VS 2028
    Table 2. Key Players of Target EGFR
    Table 3. Key Players of Target ALK
    Table 4. Key Players of Target HER2
    Table 5. Key Players of Target ROS1
    Table 6. Key Players of Target BRAF
    Table 7. Key Players of Target MEK
    Table 8. Key Players of Target VEGFR2
    Table 9. Key Players of Target VEGF
    Table 10. Key Players of Target MET
    Table 11. Global Targeted Drugs for NSCLC Market Size Growth Rate by Application (US$ Million), 2017 VS 2021 VS 2028
    Table 12. Global Targeted Drugs for NSCLC Market Size by Region (US$ Million): 2017 VS 2021 VS 2028
    Table 13. Global Targeted Drugs for NSCLC Market Size by Region (2017-2022) & (US$ Million)
    Table 14. Global Targeted Drugs for NSCLC Market Share by Region (2017-2022)
    Table 15. Global Targeted Drugs for NSCLC Forecasted Market Size by Region (2023-2028) & (US$ Million)
    Table 16. Global Targeted Drugs for NSCLC Market Share by Region (2023-2028)
    Table 17. Targeted Drugs for NSCLC Market Trends
    Table 18. Targeted Drugs for NSCLC Market Drivers
    Table 19. Targeted Drugs for NSCLC Market Challenges
    Table 20. Targeted Drugs for NSCLC Market Restraints
    Table 21. Global Targeted Drugs for NSCLC Revenue by Players (2017-2022) & (US$ Million)
    Table 22. Global Targeted Drugs for NSCLC Revenue Share by Players (2017-2022)
    Table 23. Global Top Targeted Drugs for NSCLC by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Targeted Drugs for NSCLC as of 2021)
    Table 24. Ranking of Global Top Targeted Drugs for NSCLC Companies by Revenue (US$ Million) in 2021
    Table 25. Global 5 Largest Players Market Share by Targeted Drugs for NSCLC Revenue (CR5 and HHI) & (2017-2022)
    Table 26. Key Players Headquarters and Area Served
    Table 27. Key Players Targeted Drugs for NSCLC Product Solution and Service
    Table 28. Date of Enter into Targeted Drugs for NSCLC Market
    Table 29. Mergers & Acquisitions, Expansion Plans
    Table 30. Global Targeted Drugs for NSCLC Market Size by Type (2017-2022) & (US$ Million)
    Table 31. Global Targeted Drugs for NSCLC Revenue Market Share by Type (2017-2022)
    Table 32. Global Targeted Drugs for NSCLC Forecasted Market Size by Type (2023-2028) & (US$ Million)
    Table 33. Global Targeted Drugs for NSCLC Revenue Market Share by Type (2023-2028)
    Table 34. Global Targeted Drugs for NSCLC Market Size by Application (2017-2022) & (US$ Million)
    Table 35. Global Targeted Drugs for NSCLC Revenue Share by Application (2017-2022)
    Table 36. Global Targeted Drugs for NSCLC Forecasted Market Size by Application (2023-2028) & (US$ Million)
    Table 37. Global Targeted Drugs for NSCLC Revenue Share by Application (2023-2028)
    Table 38. North America Targeted Drugs for NSCLC Market Size by Type (2017-2022) & (US$ Million)
    Table 39. North America Targeted Drugs for NSCLC Market Size by Type (2023-2028) & (US$ Million)
    Table 40. North America Targeted Drugs for NSCLC Market Size by Application (2017-2022) & (US$ Million)
    Table 41. North America Targeted Drugs for NSCLC Market Size by Application (2023-2028) & (US$ Million)
    Table 42. North America Targeted Drugs for NSCLC Market Size by Country (2017-2022) & (US$ Million)
    Table 43. North America Targeted Drugs for NSCLC Market Size by Country (2023-2028) & (US$ Million)
    Table 44. Europe Targeted Drugs for NSCLC Market Size by Type (2017-2022) & (US$ Million)
    Table 45. Europe Targeted Drugs for NSCLC Market Size by Type (2023-2028) & (US$ Million)
    Table 46. Europe Targeted Drugs for NSCLC Market Size by Application (2017-2022) & (US$ Million)
    Table 47. Europe Targeted Drugs for NSCLC Market Size by Application (2023-2028) & (US$ Million)
    Table 48. Europe Targeted Drugs for NSCLC Market Size by Country (2017-2022) & (US$ Million)
    Table 49. Europe Targeted Drugs for NSCLC Market Size by Country (2023-2028) & (US$ Million)
    Table 50. Asia Pacific Targeted Drugs for NSCLC Market Size by Type (2017-2022) & (US$ Million)
    Table 51. Asia Pacific Targeted Drugs for NSCLC Market Size by Type (2023-2028) & (US$ Million)
    Table 52. Asia Pacific Targeted Drugs for NSCLC Market Size by Application (2017-2022) & (US$ Million)
    Table 53. Asia Pacific Targeted Drugs for NSCLC Market Size by Application (2023-2028) & (US$ Million)
    Table 54. Asia Pacific Targeted Drugs for NSCLC Market Size by Region (2017-2022) & (US$ Million)
    Table 55. Asia Pacific Targeted Drugs for NSCLC Market Size by Region (2023-2028) & (US$ Million)
    Table 56. Latin America Targeted Drugs for NSCLC Market Size by Type (2017-2022) & (US$ Million)
    Table 57. Latin America Targeted Drugs for NSCLC Market Size by Type (2023-2028) & (US$ Million)
    Table 58. Latin America Targeted Drugs for NSCLC Market Size by Application (2017-2022) & (US$ Million)
    Table 59. Latin America Targeted Drugs for NSCLC Market Size by Application (2023-2028) & (US$ Million)
    Table 60. Latin America Targeted Drugs for NSCLC Market Size by Country (2017-2022) & (US$ Million)
    Table 61. Latin America Targeted Drugs for NSCLC Market Size by Country (2023-2028) & (US$ Million)
    Table 62. Middle East and Africa Targeted Drugs for NSCLC Market Size by Type (2017-2022) & (US$ Million)
    Table 63. Middle East and Africa Targeted Drugs for NSCLC Market Size by Type (2023-2028) & (US$ Million)
    Table 64. Middle East and Africa Targeted Drugs for NSCLC Market Size by Application (2017-2022) & (US$ Million)
    Table 65. Middle East and Africa Targeted Drugs for NSCLC Market Size by Application (2023-2028) & (US$ Million)
    Table 66. Middle East and Africa Targeted Drugs for NSCLC Market Size by Country (2017-2022) & (US$ Million)
    Table 67. Middle East and Africa Targeted Drugs for NSCLC Market Size by Country (2023-2028) & (US$ Million)
    Table 68. Allergan Company Details
    Table 69. Allergan Business Overview
    Table 70. Allergan Targeted Drugs for NSCLC Product
    Table 71. Allergan Revenue in Targeted Drugs for NSCLC Business (2017-2022) & (US$ Million)
    Table 72. Allergan Recent Developments
    Table 73. Amgen Company Details
    Table 74. Amgen Business Overview
    Table 75. Amgen Targeted Drugs for NSCLC Product
    Table 76. Amgen Revenue in Targeted Drugs for NSCLC Business (2017-2022) & (US$ Million)
    Table 77. Amgen Recent Developments
    Table 78. ARIAD Pharmaceuticals (Takeda) Company Details
    Table 79. ARIAD Pharmaceuticals (Takeda) Business Overview
    Table 80. ARIAD Pharmaceuticals (Takeda) Targeted Drugs for NSCLC Product
    Table 81. ARIAD Pharmaceuticals (Takeda) Revenue in Targeted Drugs for NSCLC Business (2017-2022) & (US$ Million)
    Table 82. ARIAD Pharmaceuticals (Takeda) Recent Developments
    Table 83. Beacon Pharma Limited Company Details
    Table 84. Beacon Pharma Limited Business Overview
    Table 85. Beacon Pharma Limited Targeted Drugs for NSCLC Product
    Table 86. Beacon Pharma Limited Revenue in Targeted Drugs for NSCLC Business (2017-2022) & (US$ Million)
    Table 87. Beacon Pharma Limited Recent Developments
    Table 88. BeiGene Company Details
    Table 89. BeiGene Business Overview
    Table 90. BeiGene Targeted Drugs for NSCLC Product
    Table 91. BeiGene Revenue in Targeted Drugs for NSCLC Business (2017-2022) & (US$ Million)
    Table 92. BeiGene Recent Developments
    Table 93. Biocon Company Details
    Table 94. Biocon Business Overview
    Table 95. Biocon Targeted Drugs for NSCLC Product
    Table 96. Biocon Revenue in Targeted Drugs for NSCLC Business (2017-2022) & (US$ Million)
    Table 97. Biocon Recent Developments
    Table 98. Boehringer-Ingelheim Company Details
    Table 99. Boehringer-Ingelheim Business Overview
    Table 100. Boehringer-Ingelheim Targeted Drugs for NSCLC Product
    Table 101. Boehringer-Ingelheim Revenue in Targeted Drugs for NSCLC Business (2017-2022) & (US$ Million)
    Table 102. Boehringer-Ingelheim Recent Developments
    Table 103. Celgene Corporation Company Details
    Table 104. Celgene Corporation Business Overview
    Table 105. Celgene Corporation Targeted Drugs for NSCLC Product
    Table 106. Celgene Corporation Revenue in Targeted Drugs for NSCLC Business (2017-2022) & (US$ Million)
    Table 107. Celgene Corporation Recent Developments
    Table 108. Drug International Limted Company Details
    Table 109. Drug International Limted Business Overview
    Table 110. Drug International Limted Targeted Drugs for NSCLC Product
    Table 111. Drug International Limted Revenue in Targeted Drugs for NSCLC Business (2017-2022) & (US$ Million)
    Table 112. Drug International Limted Recent Developments
    Table 113. Fujifilm Kyowa Kirin Biologics Company Details
    Table 114. Fujifilm Kyowa Kirin Biologics Business Overview
    Table 115. Fujifilm Kyowa Kirin Biologics Targeted Drugs for NSCLC Product
    Table 116. Fujifilm Kyowa Kirin Biologics Revenue in Targeted Drugs for NSCLC Business (2017-2022) & (US$ Million)
    Table 117. Fujifilm Kyowa Kirin Biologics Recent Developments
    Table 118. Genvio Pharma Limited Company Details
    Table 119. Genvio Pharma Limited Business Overview
    Table 120. Genvio Pharma Limited Targeted Drugs for NSCLC Product
    Table 121. Genvio Pharma Limited Revenue in Targeted Drugs for NSCLC Business (2017-2022) & (US$ Million)
    Table 122. Genvio Pharma Limited Recent Developments
    Table 123. Hetero Drugs Company Details
    Table 124. Hetero Drugs Business Overview
    Table 125. Hetero Drugs Targeted Drugs for NSCLC Product
    Table 126. Hetero Drugs Revenue in Targeted Drugs for NSCLC Business (2017-2022) & (US$ Million)
    Table 127. Hetero Drugs Recent Developments
    Table 128. ImClone Systems ?(Eli Lilly) Company Details
    Table 129. ImClone Systems ?(Eli Lilly) Business Overview
    Table 130. ImClone Systems ?(Eli Lilly) Targeted Drugs for NSCLC Product
    Table 131. ImClone Systems ?(Eli Lilly) Revenue in Targeted Drugs for NSCLC Business (2017-2022) & (US$ Million)
    Table 132. ImClone Systems ?(Eli Lilly) Recent Developments
    Table 133. Incepta Pharmaceuticals Company Details
    Table 134. Incepta Pharmaceuticals Business Overview
    Table 135. Incepta Pharmaceuticals Targeted Drugs for NSCLC Product
    Table 136. Incepta Pharmaceuticals Revenue in Targeted Drugs for NSCLC Business (2017-2022) & (US$ Million)
    Table 137. Incepta Pharmaceuticals Recent Developments
    Table 138. Mylan Company Details
    Table 139. Mylan Business Overview
    Table 140. Mylan Targeted Drugs for NSCLC Product
    Table 141. Mylan Revenue in Targeted Drugs for NSCLC Business (2017-2022) & (US$ Million)
    Table 142. Mylan Recent Developments
    Table 143. Novartis Company Details
    Table 144. Novartis Business Overview
    Table 145. Novartis Targeted Drugs for NSCLC Product
    Table 146. Novartis Revenue in Targeted Drugs for NSCLC Business (2017-2022) & (US$ Million)
    Table 147. Novartis Recent Developments
    Table 148. Pfizer Company Details
    Table 149. Pfizer Business Overview
    Table 150. Pfizer Targeted Drugs for NSCLC Product
    Table 151. Pfizer Revenue in Targeted Drugs for NSCLC Business (2017-2022) & (US$ Million)
    Table 152. Pfizer Recent Developments
    Table 153. Reliance Lifesciences Company Details
    Table 154. Reliance Lifesciences Business Overview
    Table 155. Reliance Lifesciences Targeted Drugs for NSCLC Product
    Table 156. Reliance Lifesciences Revenue in Targeted Drugs for NSCLC Business (2017-2022) & (US$ Million)
    Table 157. Reliance Lifesciences Recent Developments
    Table 158. Roche Company Details
    Table 159. Roche Business Overview
    Table 160. Roche Targeted Drugs for NSCLC Product
    Table 161. Roche Revenue in Targeted Drugs for NSCLC Business (2017-2022) & (US$ Million)
    Table 162. Roche Recent Developments
    Table 163. AstraZeneca Company Details
    Table 164. AstraZeneca Business Overview
    Table 165. AstraZeneca Targeted Drugs for NSCLC Product
    Table 166. AstraZeneca Revenue in Targeted Drugs for NSCLC Business (2017-2022) & (US$ Million)
    Table 167. AstraZeneca Recent Developments
    Table 168. Cipla Company Details
    Table 169. Cipla Business Overview
    Table 170. Cipla Targeted Drugs for NSCLC Product
    Table 171. Cipla Revenue in Targeted Drugs for NSCLC Business (2017-2022) & (US$ Million)
    Table 172. Cipla Recent Developments
    Table 173. Teva Company Details
    Table 174. Teva Business Overview
    Table 175. Teva Targeted Drugs for NSCLC Product
    Table 176. Teva Revenue in Targeted Drugs for NSCLC Business (2017-2022) & (US$ Million)
    Table 177. Teva Recent Developments
    Table 178. OSI Pharmaceuticals Company Details
    Table 179. OSI Pharmaceuticals Business Overview
    Table 180. OSI Pharmaceuticals Targeted Drugs for NSCLC Product
    Table 181. OSI Pharmaceuticals Revenue in Targeted Drugs for NSCLC Business (2017-2022) & (US$ Million)
    Table 182. OSI Pharmaceuticals Recent Developments
    Table 183. Glenmark Pharmaceuticals Company Details
    Table 184. Glenmark Pharmaceuticals Business Overview
    Table 185. Glenmark Pharmaceuticals Targeted Drugs for NSCLC Product
    Table 186. Glenmark Pharmaceuticals Revenue in Targeted Drugs for NSCLC Business (2017-2022) & (US$ Million)
    Table 187. Glenmark Pharmaceuticals Recent Developments
    Table 188. Natco Pharma Company Details
    Table 189. Natco Pharma Business Overview
    Table 190. Natco Pharma Targeted Drugs for NSCLC Product
    Table 191. Natco Pharma Revenue in Targeted Drugs for NSCLC Business (2017-2022) & (US$ Million)
    Table 192. Natco Pharma Recent Developments
    Table 193. Research Programs/Design for This Report
    Table 194. Key Data Information from Secondary Sources
    Table 195. Key Data Information from Primary Sources
List of Figures
    Figure 1. Global Targeted Drugs for NSCLC Market Share by Type: 2021 VS 2028
    Figure 2. Target EGFR Features
    Figure 3. Target ALK Features
    Figure 4. Target HER2 Features
    Figure 5. Target ROS1 Features
    Figure 6. Target BRAF Features
    Figure 7. Target MEK Features
    Figure 8. Target VEGFR2 Features
    Figure 9. Target VEGF Features
    Figure 10. Target MET Features
    Figure 11. Global Targeted Drugs for NSCLC Market Share by Application: 2021 VS 2028
    Figure 12. Squamous Cell Carcinoma of NSCLC Case Studies
    Figure 13. Adenocarcinoma of NSCLC Case Studies
    Figure 14. Large Cell Carcinoma of NSCLC Case Studies
    Figure 15. Targeted Drugs for NSCLC Report Years Considered
    Figure 16. Global Targeted Drugs for NSCLC Market Size (US$ Million), Year-over-Year: 2017-2028
    Figure 17. Global Targeted Drugs for NSCLC Market Size, (US$ Million), 2017 VS 2021 VS 2028
    Figure 18. Global Targeted Drugs for NSCLC Market Share by Region: 2021 VS 2028
    Figure 19. Global Targeted Drugs for NSCLC Market Share by Players in 2021
    Figure 20. Global Top Targeted Drugs for NSCLC Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Targeted Drugs for NSCLC as of 2021)
    Figure 21. The Top 10 and 5 Players Market Share by Targeted Drugs for NSCLC Revenue in 2021
    Figure 22. North America Targeted Drugs for NSCLC Market Size YoY (2017-2028) & (US$ Million)
    Figure 23. North America Targeted Drugs for NSCLC Market Size Market Share by Type (2017-2028)
    Figure 24. North America Targeted Drugs for NSCLC Market Size Market Share by Application (2017-2028)
    Figure 25. North America Targeted Drugs for NSCLC Market Size Share by Country (2017-2028)
    Figure 26. United States Targeted Drugs for NSCLC Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 27. Canada Targeted Drugs for NSCLC Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 28. Europe Targeted Drugs for NSCLC Market Size YoY (2017-2028) & (US$ Million)
    Figure 29. Europe Targeted Drugs for NSCLC Market Size Market Share by Type (2017-2028)
    Figure 30. Europe Targeted Drugs for NSCLC Market Size Market Share by Application (2017-2028)
    Figure 31. Europe Targeted Drugs for NSCLC Market Size Share by Country (2017-2028)
    Figure 32. Germany Targeted Drugs for NSCLC Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 33. France Targeted Drugs for NSCLC Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 34. U.K. Targeted Drugs for NSCLC Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 35. Italy Targeted Drugs for NSCLC Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 36. Russia Targeted Drugs for NSCLC Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 37. Nordic Countries Targeted Drugs for NSCLC Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 38. Asia-Pacific Targeted Drugs for NSCLC Market Size YoY (2017-2028) & (US$ Million)
    Figure 39. Asia Pacific Targeted Drugs for NSCLC Market Size Market Share by Type (2017-2028)
    Figure 40. Asia Pacific Targeted Drugs for NSCLC Market Size Market Share by Application (2017-2028)
    Figure 41. Asia Pacific Targeted Drugs for NSCLC Market Size Share by Region (2017-2028)
    Figure 42. China Targeted Drugs for NSCLC Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 43. Japan Targeted Drugs for NSCLC Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 44. South Korea Targeted Drugs for NSCLC Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 45. Southeast Asia Targeted Drugs for NSCLC Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 46. India Targeted Drugs for NSCLC Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 47. Australia Targeted Drugs for NSCLC Market Size YoY Growth (2017-2028) & (US$ Million)
List of Figures
    Figure 48. Latin America Targeted Drugs for NSCLC Market Size YoY (2017-2028) & (US$ Million)
    Figure 49. Latin America Targeted Drugs for NSCLC Market Size Market Share by Type (2017-2028)
    Figure 50. Latin America Targeted Drugs for NSCLC Market Size Market Share by Application (2017-2028)
    Figure 51. Latin America Targeted Drugs for NSCLC Market Size Share by Country (2017-2028)
    Figure 52. Mexico Targeted Drugs for NSCLC Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 53. Brazil Targeted Drugs for NSCLC Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 54. Middle East & Africa Targeted Drugs for NSCLC Market Size YoY (2017-2028) & (US$ Million)
    Figure 55. Middle East and Africa Targeted Drugs for NSCLC Market Size Market Share by Type (2017-2028)
    Figure 56. Middle East and Africa Targeted Drugs for NSCLC Market Size Market Share by Application (2017-2028)
    Figure 57. Middle East and Africa Targeted Drugs for NSCLC Market Size Share by Country (2017-2028)
    Figure 58. Turkey Targeted Drugs for NSCLC Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 59. Saudi Arabia Targeted Drugs for NSCLC Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 60. UAE Targeted Drugs for NSCLC Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 61. Allergan Revenue Growth Rate in Targeted Drugs for NSCLC Business (2017-2022)
    Figure 62. Amgen Revenue Growth Rate in Targeted Drugs for NSCLC Business (2017-2022)
    Figure 63. ARIAD Pharmaceuticals (Takeda) Revenue Growth Rate in Targeted Drugs for NSCLC Business (2017-2022)
    Figure 64. Beacon Pharma Limited Revenue Growth Rate in Targeted Drugs for NSCLC Business (2017-2022)
    Figure 65. BeiGene Revenue Growth Rate in Targeted Drugs for NSCLC Business (2017-2022)
    Figure 66. Biocon Revenue Growth Rate in Targeted Drugs for NSCLC Business (2017-2022)
    Figure 67. Boehringer-Ingelheim Revenue Growth Rate in Targeted Drugs for NSCLC Business (2017-2022)
    Figure 68. Celgene Corporation Revenue Growth Rate in Targeted Drugs for NSCLC Business (2017-2022)
    Figure 69. Drug International Limted Revenue Growth Rate in Targeted Drugs for NSCLC Business (2017-2022)
    Figure 70. Fujifilm Kyowa Kirin Biologics Revenue Growth Rate in Targeted Drugs for NSCLC Business (2017-2022)
    Figure 71. Genvio Pharma Limited Revenue Growth Rate in Targeted Drugs for NSCLC Business (2017-2022)
    Figure 72. Hetero Drugs Revenue Growth Rate in Targeted Drugs for NSCLC Business (2017-2022)
    Figure 73. ImClone Systems ?(Eli Lilly) Revenue Growth Rate in Targeted Drugs for NSCLC Business (2017-2022)
    Figure 74. Incepta Pharmaceuticals Revenue Growth Rate in Targeted Drugs for NSCLC Business (2017-2022)
    Figure 75. Mylan Revenue Growth Rate in Targeted Drugs for NSCLC Business (2017-2022)
    Figure 76. Novartis Revenue Growth Rate in Targeted Drugs for NSCLC Business (2017-2022)
    Figure 77. Pfizer Revenue Growth Rate in Targeted Drugs for NSCLC Business (2017-2022)
    Figure 78. Reliance Lifesciences Revenue Growth Rate in Targeted Drugs for NSCLC Business (2017-2022)
    Figure 79. Roche Revenue Growth Rate in Targeted Drugs for NSCLC Business (2017-2022)
    Figure 80. AstraZeneca Revenue Growth Rate in Targeted Drugs for NSCLC Business (2017-2022)
    Figure 81. Cipla Revenue Growth Rate in Targeted Drugs for NSCLC Business (2017-2022)
    Figure 82. Teva Revenue Growth Rate in Targeted Drugs for NSCLC Business (2017-2022)
    Figure 83. OSI Pharmaceuticals Revenue Growth Rate in Targeted Drugs for NSCLC Business (2017-2022)
    Figure 84. Glenmark Pharmaceuticals Revenue Growth Rate in Targeted Drugs for NSCLC Business (2017-2022)
    Figure 85. Natco Pharma Revenue Growth Rate in Targeted Drugs for NSCLC Business (2017-2022)
    Figure 86. Bottom-up and Top-down Approaches for This Report
    Figure 87. Data Triangulation
    Figure 88. Key Executives Interviewed